Faculty
We are delighted to confirm the following international faculty for the 2025 SABR Symposium.
Pierre Blanchard
Dr Blanchard is a full Professor of radiation oncology at Gustave Roussy Cancer Center, France. He has developed a clinical expertise in the field of Head and Neck radiotherapy, Genitourinary radiotherapy and brachytherapy as well as proton therapy. In parallel to his medical training, he performed a PhD in Public Health on Biostatistics and individual patient data meta-analyses. He is currently the clinical coordinator of the Head and Neck meta-analyses performed at Gustave Roussy (> 200 trials, 5 individual patient data meta-analyses). He is very active within the internationally recognized head and neck research groups GORTEC (head and neck oncology) and GETUG (urologic oncology). He is the primary investigator of randomized phase III trials on prostate cancers and head and neck cancers, specifically for HPV-induced cancers. Dr Blanchard also serves as faculty for different courses organized at Gustave Roussy and is currently responsible for a national teaching course on head and neck radiotherapy. He has published more than 200 articles in peer-reviewed journals and is a frequent reviewer for major journals, including The Lancet and the New England Journal of Medicine. He is currently an adjunct Professor at the UT MD Anderson Cancer Center, after having spent two years there as a visiting Faculty, and the Editor-in-Chief of Radiotherapy & Oncology (https://www.thegreenjournal.com/) since May 2024. He has been appointed in 2019 as the Director of Gustave Roussy’s School of Cancer Sciences, and is now since 2024 the General Secretary of Gustave Roussy Education.
Barbara Jereczek-Fossa
Barbara Alicja Jereczek-Fossa, MD, PhD, is a Full Professor of Radiation Oncology at the Department of Oncology and Hemato-oncology at the University of Milan (UNIMI), Italy, and Chair of the Department of Radiation Oncology at the European Institute of Oncology IRCCS (IEO), Milan, Italy.
Prof. Jereczek-Fossa is President Elect of the European Society of Radiotherapy and Oncology (ESTRO) and actively contributes to various scientific societies, committees, advisory and editorial boards, including the Panel of the Advanced Prostate Cancer Consensus Conference (APCCC) and the Scientific Board of the European School of Oncology (ESO).
She serves as Principal Investigator for Italian Association of Cancer Research (AIRC) funded studies, including the RADIOSA trial on prostate cancer oligorecurrences, the GREEN Radiotherapy initiative exploring sustainable hypofractionation (within Multilayered Urban Sustainability Action MUSA project), cardiac radioablation phase I/II STRA-MI-VT study, and trials regarding combination of radiotherapy with new drugs. Her research portfolio also includes projects on AI and radiomics (e.g., DECIDE), lifestyle interventions (MICROSTYLE), and international projects like EORTC-ESTRO’s E²-RADIatE (collaboration).
Prof. Jereczek-Fossa is an author or co-author of almost 500 peer-reviewed scientific articles and 8 book chapters; and with her H-index of 57, she is listed among the Top Italian Scientists and at Stanford University World’s Top 2% Scientists.
Lauren Henke
Lauren Henke, MD, MSCI is an Associate Professor of Radiation Oncology and Director of the GI Radiation Oncology service at University Hospitals/Case Western Reserve University in Cleveland, Ohio, where she also co-leads the GI Oncology Disease Team for Seidman Cancer Center and serves as residency Program Director. Her clinical specialty is the treatment of gastrointestinal cancers. She has specialized in the development and clinical implementation of advanced technologies, like advanced CT- and MRI-guided radiotherapy, since 2014. She has led multiple prospective clinical trials of online adaptive radiotherapy using both CT and MRI guidance. These include the first-ever clinical trial of stereotactic MR-guided online-adaptive RT (SMART) and an ongoing Phase II prospective clinical trial of CT-guided stereotactic adaptive radiotherapy for borderline resectable and locally advanced pancreatic cancer. Dr. Henke also serves on the National Cancer Institute (NCI) Task Force on pancreatic cancer, the NRG Oncology task groups for pancreas and hepatobiliary cancers, and is the physician chair of the ASTRO task force on adaptive radiotherapy.
Drew Moghanaki
Dr. Drew Moghanaki is Professor, Chief of Thoracic Oncology, and the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the UCLA Department of Radiation Oncology. He has a joint appointment in the Veterans Health Administration, where he leads over $50 million in lung cancer early detection and clinical trial activities; this includes the VA Partnership to Increase Access to Lung Screening (VA-PALS) and phase III randomized clinical trial evaluating SBRT for operable stage I lung cancer (VALOR).
Melissa O’Neil
Melissa O’Neil is an Advanced Practice Radiation Therapist at the London Regional Cancer Program, specializing in palliative and stereotactic radiotherapy. She leads the Rapid Response Clinic, a service designed to ensure expedient access to palliative radiation for symptomatic patients, and is an integral part of the stereotactic multidisciplinary team. Melissa's areas of expertise include image guidance, motion management, peer education, and oligo/polymetastatic clinical trial implementation. Her research on sim-free palliative radiotherapy comprised her master’s dissertation in Advanced Practice in Radiotherapy and Oncology, and she earned an MSc with Distinction from Sheffield Hallam University in 2023.